Gotham Asset Management LLC Acquires New Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Gotham Asset Management LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 18,196 shares of the company's stock, valued at approximately $440,000.

Several other hedge funds have also recently made changes to their positions in the company. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth approximately $38,000. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HIMS shares. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and reduced their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Morgan Stanley reduced their target price on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Tuesday, April 29th. Finally, Citigroup reissued a "sell" rating and set a $30.00 target price (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Trading Down 1.8%

HIMS stock traded down $1.13 during trading on Tuesday, reaching $61.21. The stock had a trading volume of 35,648,545 shares, compared to its average volume of 19,324,174. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The stock's 50 day moving average is $36.60 and its two-hundred day moving average is $34.38. The firm has a market cap of $13.70 billion, a PE ratio of 139.12 and a beta of 1.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter in the prior year, the company earned $0.05 earnings per share. Hims & Hers Health's revenue was up 110.7% on a year-over-year basis. On average, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the sale, the chief financial officer now owns 113,816 shares of the company's stock, valued at approximately $6,853,999.52. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Melissa Baird sold 33,333 shares of Hims & Hers Health stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares in the company, valued at $20,755,039.74. This trade represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 618,936 shares of company stock valued at $25,182,692. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.